Home/ Stocks/ IPSC

Century Therapeutics, Inc. Common Stock

IPSC XNAS

$2.00 +0.10 (+5.26%) ▲ 15-min delayed

Open

$1.92

High

$2.02

Low

$1.90

Volume

522.6K

Market Cap

$342.67M

About Century Therapeutics, Inc. Common Stock

Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 78 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-21,645,000	$-0.11
FY 2025	$109.16M	$-9,580,000	$-0.14
Q3 2025	$0	$-34,422,000	$-0.40
Q2 2025	$0	$-32,541,000	$-0.38

Related Market News

No specific coverage for IPSC yet. Check out our latest market news or earnings calendar.

Get IPSC Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Century Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.